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This data article describes serum glycoprotein biomarker discovery
and qualiﬁcation datasets generated using lectin magnetic bead
array (LeMBA) – mass spectrometry techniques, “Serum glyco-
protein biomarker discovery and qualiﬁcation pipeline reveals
novel diagnostic biomarker candidates for esophageal adeno-
carcinoma” [1]. Serum samples collected from healthy, metaplastic
Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC)
individuals were proﬁled for glycoprotein subsets via differential
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Dconsisting of 20 individual lectin pull-downs for 29 serum samples
with a spiked-in internal standard chicken ovalbumin protein has
been deposited in the PRIDE partner repository of the Proteo-
meXchange Consortium with the data set identiﬁer PRIDE:
PXD002442. Annotated MS/MS spectra for the peptide identiﬁca-
tions can be viewed using MS-Viewer (〈http://prospector2.ucsf.
edu/prospector/cgi-bin/msform.cgi?form¼msviewer〉) using
search key “jn7qafftux”. The qualiﬁcation dataset contained 6-
lectin pulldown-coupled multiple reaction monitoring-mass
spectrometry (MRM-MS) data for 41 protein candidates, from 60
serum samples. This dataset is available as a supplemental ﬁles
with the original publication [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biologyore speciﬁc sub-
ject areaGlyco-centric proteomics analysis for serum biomarker discovery and
qualiﬁcationype of data Table, Figure, Graph, Western-blot images
ow data was
acquiredThe data for the biomarker discovery screen was acquired using an Agilent
6520 quadrupole time of ﬂight (QTOF) coupled with a Chip Cube and 1200
HPLC. The targeted proteomics for the biomarker qualiﬁcation was performed
on an Agilent Technologies 6490 triple quadrupole mass spectrometer cou-
pled with a 1290 standard-ﬂow inﬁnity UHPLC ﬁtted with an electrospray
ionization source.ata format Raw, processed and analyzed.
xperimental
factorsDenatured serum samples (50 μg of protein per lectin pulldown) were spiked
with an internal standard chicken ovalbumin (10 pmol per lectin pulldown),
reduced and then alkylated [1].xperimental
featuresUsing semi-automated high-throughput workﬂow lectin magnetic bead array
(LeMBA) [1–3], glycoproteins were enriched from serum samples using lectin
coated magnetic beads (20 individual lectin-beads for biomarker discovery
and 6 individual lectin-beads for biomarker qualiﬁcation). The lectin pull-
downs were subjected to on-bead trypsin digestion followed by mass spec-
trometric analyses for protein identiﬁcation and relative quantitation.ata source
locationUQ Diamantina Institute, Translational Research Institute, Brisbane, Queens-
land, Australia.ata accessibility Data available within this article. The proteomics data can be accessed
through the ProteomeXchange Consortium via the PRIDE partner repository
with the data set identiﬁer PRIDE: PXD002442.Value of the data
 Serum glycoprotein sub-fraction according to lectin binding to 20 different lectins, for 3 patient
groups from healthy, Barrett's esophagus and esophageal adenocarcinoma.
 Label free quantitation in relation to an internal standard protein across 1054 mass
spectrometric runs.
 The data can be used to compare lectin-pulldown proteomes from different serum samples/
conditions.
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Raw QTOF spectra, searched peptide-spectrum matches and protein level quantitation for serum
proteins isolated by binding to each of 20 lectins per serum sample for biomarker discovery. Peptide
and protein level quantitation for serum proteins isolated by 6 individual lectin per serum sample for
biomarker qualiﬁcation. The serum samples have been categorized to healthy, Barrett's esophagus or
esophageal adenocarcinoma according to clinical information.2. Experimental design, material and methods
To proﬁle differentially glycosylated serum proteins between disease conditions, each serum
sample was subjected to parallel pulldown using 20 different lectins, prior to on-bead tryptic digestFig. 1. Workﬂow for data acquisition. Individual serum samples from patient cohorts were subjected to lectin magnetic bead
array pulldown before mass spectrometry analysis. Discovery data were obtained using 20 different lectins, and analyzed by
QTOF mass spectrometer with an internal reference protein between samples. Qualiﬁcation data were obtained using 6 dif-
ferent lectins and analyzed by QQQ mass spectrometer using a scheduled MRM assay [1].
A.K. Shah et al. / Data in Brief 7 (2016) 1058–1062 1061and LC-MS analysis (Fig. 1). The lectins used are: AAL, BPL, ConA, DSA, ECA, EPHA, GNL, HAA, HPA, JAC,
LPHA, MAA, NPL, PSA, SBA, SNA, STL, UEA, WFA and WGA [2].
2.1. Serum sample collection
The study was approved by The University of Queensland Human Ethics Committees. Serum
samples from healthy, Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) individuals
were collected as a part of ACS [4] and SDH [5] research programs, with written informed consent.
Serum from 10 ml of whole blood was processed and stored at 80 °C until use. Typically, samples
were thawed once for protein estimation and simultaneously denatured. The serum samples used for
the biomarker discovery phase (Healthy-9, BE-10 and EAC-10) and the biomarker qualiﬁcation study
(Healthy-20, BE-20, EAC-20 and population control-19) were age and gender matched.
2.2. Sample preparation and LeMBA pull-down
Serum samples were denatured, spiked with 10 pmol chicken ovalbumin per lectin pull-down as
an internal standard, reduced, and alkylated prior to Lectin magnetic bead array (LeMBA). LeMBA and
on-bead tryptic digestion was performed as describe previously using a Bravo liquid handler [1–3].
LeMBA – MS/MS was performed for biomarker discovery while LeMBA – MRM-MS was performed for
the biomarker qualiﬁcation stages.
2.3. Mass spectrometric analyzes and data processing
For biomarker discovery, samples were subjected to data dependent mass spectrometric analyzes
using nano-ﬂow LC-MS/MS (1200 HPLC, Agilent Technologies) coupled with an Agilent 6520 quad-
rupole time of ﬂight [QTOF] with a Chip Cube interface. Out of total 20 ml of trypsin digested sample in
0.1% v/v formic acid, varying amount according to individual lectin pull-down was injected for mass
spectrometric analyzes. Those were 9 μl for HAA, HPA and UEA, 6 μl for NPL, STL, GNL, 5 μl for BPL,
DSA, ECA, MAA, SBA, WFA, and WGA, 4 μl for AAL, SNA, LPHA, PSA and JAC, 1 μl for EPHA and ConA. In
total, 609 samples [(20 lectinsþempty beads)29 samples)] were processed across 896 well-
plates and run on the mass spectrometer taking up approximately 1000 h of the instrument time. The
data were extracted and searched against the Swiss-prot human database containing 20,242 entries
(release 3rd Jan 2012) using the Spectrum Mill MS proteomics workbench (Agilent Technologies, Rev.
B.04.00.127). Raw data (.d ﬁles), processed ﬁles (pepXML and.pkl ﬁles), and analyzed data (.xlsx) can
be accessed through the ProteomeXchange Consortium [6] via the PRIDE [7] partner repository with
the data set identiﬁer PRIDE: PXD002442. The annotated spectra have been made available through
the MS-Viewer (〈http://prospector2.ucsf.edu/prospector/cgi-bin/msform.cgi?form¼msviewer〉) [8]
and can be accessed using search key “jn7qafftux”. The data made available through PRIDE and MS-
Viewer are named using the format “yyyymmdd_initials_lectin abbreviation-sample number”. In
addition, the data can be accessed through GlycoSelector (〈http://glycoselector.di.uq.edu.au/index.
php〉) where readers can process and visualize these data using tools available within GlycoSelector.
The patient information provided in Supplementary Table 1 can be used for data processing, parti-
cularly to categorize the raw data into patient groups.
For biomarker qualiﬁcation, an MRM-MS assay was set up on an Agilent Technologies 6490 triple
quadrupole mass spectrometer coupled with a 1290 standard-ﬂow inﬁnity UHPLC and ﬁtted with a
standard-ﬂow ESI (Jet Stream). The assay quantiﬁed 41 protein candidates incorporating a total of 140
peptides (2–5 peptides per protein) and 426 transitions (Z2 transitions per peptide) (Supplemental
Table 6 of Shah et al. [1]). A 34 min long chromatographic method (24 min of actual gradient) was
enough to accommodate all the transitions. The data visualization and peak integration steps were
performed using Skyline version 2.1.0.4936 [9]. Six (AAL, EPHA, JAC, NPL, PSA, and WGA) out of 20
lectins were chosen for LeMBA pull-down. 79 samples including healthy, BE, EAC with additional
population controls were processed using LeMBA-MRM-MS (6 lectins79 samples¼474 samples).
The peptide level data were also converted into protein intensities. Proteins for which more than 50%
of the peptides did not show a Pearson correlation coefﬁcient of more than 0.6 were removed from
A.K. Shah et al. / Data in Brief 7 (2016) 1058–10621062the data set. For protein quantiﬁcation, peptide(s) that did not show a Pearson correlation coefﬁcient
40.6 with the majority (450%) of the measured peptides from the same protein were eliminated as
outliers. Equal weight was given to each peptide irrespective of its absolute intensity when calcu-
lating a normalized protein intensity. A total of 238 lectin-protein candidates were quantiﬁed. The
normalized peptide-level intensity data are given in an Excel ﬁle as Supplemental Table 7 of Shah
et al. [1]. Supplementary Table 2 incorporates details of samples used for biomarker qualiﬁcation.
The datasets were normalized according to internal standard chicken ovalbumin responses. For
biomarker discovery, at least three ovalbumin peptide intensities were selected to calculate the
normalized response. For biomarker qualiﬁcation, a two-step normalization approach was under-
taken. In ﬁrst step, the datasets were adjusted for mass spectrometric variations using isotopically
labeled ovalbumin peptide. While second step normalization using internal standard chicken oval-
bumin peptide accounted for variations in sample handling and lectin pull-downs. Collectively the
data generated using LeMBA-LC-MS/MS, and LeMBA-LC-MRM-MS are available either via public
repositories or along with the original publication [1].Acknowledgments
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